As the costs of bringing drugs to market continue to rise and pricing pressure bites, pharma is looking for new ways to create value and drive efficiencies, including partnering with tech giants and agile start-ups to create technology solutions that lead to improved and diversified revenue streams. In doing so, pharma companies must self-disrupt to stay ahead in an increasingly competitive and demanding market.
Articles & Features
The life sciences industry’s commitment to digital transformation is increasing, but few organizations are digitally maturing. Here’s how companies can take an enterprisewide approach to digital transformation.
Lot-to-lot variability is a common problem in bioprocess manufacturing, one that frustrates efforts to plan more effectively for downstream output. Pressure to achieve lot-to-lot consistency has intensified in recent years. This is partly due to more stringent regulatory requirements, in particular around trace metals. The pressure also reflects internal demand for manufacturing efficiencies, as biopharmaceutical companies grapple with issues such as rising drug-development costs and tougher barriers to market access.
Safe and efficient delivery is a fundamental challenge for personalized medicine, gene therapy and genetic medicine. Specialized and unique delivery systems are required, depending on the biology and the physiology of the target. Of the many and varied efforts to develop controlled-release, nano-compartmentalized therapeutic agents, Liposomes and Lipid-nanoparticle (LNP) systems are two of the most promising.
In the 12th edition of EY’s medtech report, The Pulse of the Industry, we examine the annual performance of the medical device industry in the context of the technological advances and rising customer expectations associated with the Fourth Industrial Revolution. To thrive in this transformative age, medtechs must adapt their business models to meet the increased expectations of consumers and other health care stakeholders.
An increasingly data-rich healthcare sector presents both opportunities and challenges for the MedTech industry, just as it does for the health systems and patients served by MedTech products.
Used intelligently and appropriately, the vast quantities of real-world data emanating from multiple healthcare sources, such as electronic medical records (EMRs), claims databases, products and disease registries, provide the raw material for real-world evidence (RWE) that can inform strategy and decision-making throughout the MedTech-product lifecycle.
Mike Ward, head of pharma content, sat down with Srinivasa Karri, a strategist with Oracle Health Sciences, to discuss the survey findings and highlight how companies can best manage the torrent of clinical data from multiple sources that will underpin their regulatory submissions.
US FDA is an ever-evolving organization, from recent changes to facility inspections under its so-called "Program Alignment" initiative, to plans to harmonize the agency's Quality System Regulation with international quality systems standard ISO 13485 – just to name two big-ticket reforms.
Adoptive Cellular Transfer (ACT): Novel Cancer Trials Demand That Participating Sites Act Differently
As more pharma and biotech companies bring their ACT platforms to the clinic, there is a need for the assistance of clinical research organisations (CROs) to support the conduct of clinical trials. Valued for their relationships with trial centres, CROs have been thrust into the forefront of operationalising ACT studies. So what can sites expect and commit to when participating in ACT trials?
Downloads & Multimedia
|Pharma Asset Insights eBook||Download PDF|
|Clinical & Research Excellence Awards 2018 eBook||Download PDF|
|Global Generics & Biosimilars Awards 2018||Download PDF|
| Research Reports
|Addressing the Data Challenges of Pharmacovigilance||Download PDF|
|How to Efficiently Manage Clinical Trial Comparator Sourcing Challenges||Download PDF|
|Clinical Trial Randomization and Supply Management Systems of Tomorrow||View Video|
|Addressing the Data Challenges of Pharmacovigilance||View Video|
|Simplifying Regulatory Processes For Post-approval Changes With Unified RIM||Register|
|More Patients, Faster. The Next Evolution Of Oncology Drug Development||Register|
|Disrupting The Status Quo Of eClinical Identity Management: Removing The Burden At Clinical Trial Sites||Register|
|Does the UK’s Life Sciences Industrial Strategy And Sector Deal Make Brexit Easier to Swallow?||Register|
|Addressing Key Challenges In The Clinical Development Of Combination Immuno-oncology Therapies||Register|
|eConsent: Better For The Patient, Better For The Site||Register|
|What's Next In eCOA? - New Insights Into Equivalence Testing Methodology And Implications For BYOD||Register|
|Using Innovative Materials To Drive Medical Device Design||Register|
|Using Innovative Materials To Drive Medical Device Design - Part 2||Register|
|Body Fluids Analysis With Linearity Down to Zero||Register|
| Whitepapers & Special Reports
|Getting It Right – Drawing Together Key Stakeholders To Shape The Real-World Data Revolution||Download PDF|
|Accelerating Cancer Drug Development||Download PDF|
|Improving Pharma R&D Efficiency: The Case for a Holistic Approach to Transforming Clinical Trials||Download PDF|
|Meeting Growth Challenges Roundtable||Download PDF|
|Innovation UK: Pushing life science frontiers in the North of England||Download PDF|
|Medical Devices Aren’t Luxury Goods, So Why Does Medtech Try to Sell Them That Way?||Download PDF|
|Translating Innovation Medtech Made Local||Download PDF|
|Positioning Key Accounts at the Center of Medtech’s Commercial Model||Download PDF|
|Assessing Patient Availability||Download PDF|
|Adaptive Design Years Later; What have we learned?||Download PDF|
|Applying Disruptive Innovation in CNS Clinical Trials to Reduce Variability||Download PDF|
|Cell And Gene Therapy Rapid Approvals Can Pose Commercialization Challenges||Download PDF|
|Successful Linguistic Validation of Clinical Outcomes Assessments||Download PDF|
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.